These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24014249)

  • 21. Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with Ritonavir-boosted protease inhibitor monotherapy.
    Neth O; Falcon-Neyra L; Ruiz-Valderas R; León Leal JA; Obando I; Alvarez Del Vayo Benito C; Lopez-Cortes LF
    Pediatr Infect Dis J; 2011 Oct; 30(10):917. PubMed ID: 21915022
    [No Abstract]   [Full Text] [Related]  

  • 22. Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials.
    Poveda E; Vispo E; Pattery T; de Mendoza C; Villacian J; Soriano V
    J Antimicrob Chemother; 2007 Dec; 60(6):1411-3. PubMed ID: 17911388
    [No Abstract]   [Full Text] [Related]  

  • 23. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial.
    Arribas J; Hill A; Xi N; van Delft Y; Moecklinghoff C
    J Antimicrob Chemother; 2012 Jul; 67(7):1804-6. PubMed ID: 22454490
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.
    Benard A; van Sighem A; Taieb A; Valadas E; Ruelle J; Soriano V; Calmy A; Balotta C; Damond F; Brun-Vezinet F; Chene G; Matheron S;
    Clin Infect Dis; 2011 May; 52(10):1257-66. PubMed ID: 21507923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using ritonavir with indinavir in cases of virologic failure.
    TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
    [No Abstract]   [Full Text] [Related]  

  • 27. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy.
    Lambert-Niclot S; Flandre P; Valantin MA; Peytavin G; Duvivier C; Haim-Boukobza S; Algarte-Genin M; Yazdanpanah Y; Girard PM; Katlama C; Calvez V; Marcelin AG
    J Infect Dis; 2011 Oct; 204(8):1211-6. PubMed ID: 21917894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.
    Gutmann C; Cusini A; Günthard HF; Fux C; Hirschel B; Decosterd LA; Cavassini M; Yerly S; Vernazza PL;
    AIDS; 2010 Sep; 24(15):2347-54. PubMed ID: 20802298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.
    Lathouwers E; De La Rosa G; Van de Casteele T; Baeten B; Tomaka F; De Meyer S; Picchio G
    Antivir Ther; 2013; 18(3):289-300. PubMed ID: 23558157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
    Descamps D; Lambert-Niclot S; Marcelin AG; Peytavin G; Roquebert B; Katlama C; Yeni P; Felices M; Calvez V; Brun-Vézinet F
    J Antimicrob Chemother; 2009 Mar; 63(3):585-92. PubMed ID: 19147519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.
    Nelson M; Girard PM; Demasi R; Chen L; Smets E; Sekar V; Lavreys L
    J Antimicrob Chemother; 2010 Jul; 65(7):1505-9. PubMed ID: 20498120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [From HAART to "smart": maximizing the advantages of lopinavir/ritonavir].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():68-9. PubMed ID: 15373055
    [No Abstract]   [Full Text] [Related]  

  • 35. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1.
    Viganò A; Meroni L; Marchetti G; Vanzulli A; Giacomet V; Fasan S; Pradella A; Cerini C; Zuccotti GV
    Antivir Ther; 2008; 13(6):839-43. PubMed ID: 18839785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
    Santos JR; Llibre JM; Domingo P; Imaz A; Ferrer E; Podzamczer D; Bravo I; Ribera E; Videla S; Clotet B
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):713-7. PubMed ID: 21114458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
    Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA;
    BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
    Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
    Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
    Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.